• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

    119.81 +31.97 (+36.39%)
    Streaming Delayed Price Updated: 1:28 PM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 888,491
    Open 113.00
    Bid (Size) 118.71 (200)
    Ask (Size) 121.00 (400)
    Prev. Close 87.84
    Today's Range 109.00 - 127.69
    52wk Range 18.23 - 114.69
    Shares Outstanding 98,935,025
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill

    Performance

    YTD
    +19.5%
    +19.5%
    1 Month
    +37.7%
    +37.7%
    3 Month
    +22.2%
    +22.2%
    6 Month
    +139.0%
    +139.0%
    1 Year
    +499.3%
    +499.3%

    More News

    Read More
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 11, 2025 ↗
    Via Benzinga
    News headline image
    Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Wider Q2 2025 Loss, Stock Drops 13% Despite Clinical Progress ↗
    Via Chartmill

    Frequently Asked Questions

    Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
    Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
    The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
    What is the current price of Palvella Therapeutics, Inc. - Common Stock?
    The current price of Palvella Therapeutics, Inc. - Common Stock is 119.81
    When was Palvella Therapeutics, Inc. - Common Stock last traded?
    The last trade of Palvella Therapeutics, Inc. - Common Stock was at 02/24/26 01:28 PM ET
    What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
    The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 11.85B
    How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
    Palvella Therapeutics, Inc. - Common Stock has 12B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.